Noting that only 25 percent of incidental emboli are identified in reporting of initial computed tomography (CT) exams, Avicenna.AI said the artificial intelligence (AI)-enabled CINA-iPE is geared toward detecting incidental pulmonary embolism (PE) on chest CT scans.
Avicenna.AI has launched CINA-iPE, an artificial intelligence (AI)-powered modality, which may facilitate the diagnosis of incidental pulmonary embolism (PE) on chest computed tomography (CT) examinations.
The company noted that CINA-iPE, which utilizes AI to analyze chest CT scans for incidental PE, is the first modality for CINA Incidental, a new suite of imaging tools geared toward enhancing CT diagnosis of unsuspected pathologies.
While incidental PE is frequently detected on chest CT, Avicenna.AI emphasized that incidental PE is a significant cause of mortality among patients with cancer and maintained that incidental emboli are commonly missed in reporting for initial CT assessments.
“Pulmonary embolism is a dangerous, life-threatening condition and with CINA-iPE, we hope to increase the number of patients identified with incidental PE and help improve their outcomes,” noted Cyril Di Grandi, cofounder and chief executive officer of Avicenna.AI.
Avicenna.AI said it will debut CINA-iPE at the European Congress of Radiology March 1-5, 2023 in Vienna, Austria.
(Editor’s note: For related content, see “Viz.ai Launches AI-Powered Vascular Imaging Software” and “PE Triage Platform from RapidAI Receives FDA 510(k) Clearance.”)
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.